Illumina weakness ‘overdone,’ says Wolfe Research
Wolfe Research reiterated an Outperform rating and $150 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about ...
Roche SBX announcement creates more uncertainty for Illumina, says RBC
RBC Capital reiterated an Outperform rating and $247 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about its ...
Benzinga.com10d
Decoding Illumina's Options Activity: What's the Big Picture?
Deep-pocketed investors have adopted a bullish approach towards Illumina ILMN, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...
Illumina Forecasts 2025 Revenue Largely Below Estimates
The company forecast annual revenue of $4.28 billion to $4.4 billion for 2025, the midpoint of which is below analysts' ...